Avelumab and Merkel Cell Carcinoma: Examining the Evidence on Risk and Causation

From General Health to Occupational Exposure: The Legacy Context

In the domain of mass production, the legacy of general health and science information has long emphasized broad preventive measures and population-level wellness. This heritage traditionally focused on lifestyle factors, environmental hygiene, and the avoidance of common pathogens, providing a foundational understanding of how external agents can influence human health. As industrial processes have evolved, however, the scope of inquiry has necessarily expanded to include more specific exposures encountered in occupational settings. The transition from this general health context to a more targeted concern involves recognizing that certain substances used in manufacturing may carry distinct risks that require specialized investigation. One such area of emerging interest is the potential link between exposure to the therapeutic monoclonal antibody Avelumab—increasingly utilized in production environments related to biologic pharmaceuticals—and the risk of developing Merkel cell carcinoma. While the legacy framework would address this through broad toxicological principles, the occupational exposure concern demands a focused examination of how workers in mass production facilities might encounter this agent. This pivot does not presuppose causation but rather acknowledges the need to evaluate whether routine handling or incidental contact in industrial settings could contribute to carcinogenic risk, thereby bridging from general health awareness to a specific, workplace-centered inquiry.

Bridging to the Evidence: Avelumab as a Therapeutic Agent

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication and is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Merkel Cell Carcinoma: Causes and Risk Factors

Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus, with approximately 80% of cases caused by the human Merkel cell polyomavirus and the remaining 20% induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/; https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence rate of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1), offer durable responses and significant clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Additionally, 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/).

Risk Context: Non-Response and Progression on Avelumab

For patients who are refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a retrospective study conducted at three academic sites in Germany, clinical and molecular data from patients with metastatic MCC refractory to avelumab and subsequently treated with combined ipilimumab and nivolumab were collected and evaluated (https://pubmed.ncbi.nlm.nih.gov/33439294/). Three out of five patients investigated responded to combined ipilimumab and nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported on ipilimumab plus nivolumab in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC further supports the use of this combination in patients who have progressed on avelumab (https://pubmed.ncbi.nlm.nih.gov/35877101/). Regarding causation-related considerations, the evidence indicates that avelumab is not a cause of Merkel cell carcinoma but rather a therapeutic agent used to treat it. The risk narrative centers on the adequacy of warnings regarding avelumab's efficacy and adverse effects in the context of MCC. The primary risk for patients is the potential for lack of response or progression on avelumab therapy, as approximately 50% of patients do not respond or develop immune-related adverse events (https://pubmed.ncbi.nlm.nih.gov/34445385/). The timeline between exposure to avelumab and documented harm, such as disease progression or adverse events, is variable and depends on individual patient factors and tumor biology. The JAVELIN Merkel 200 trial provided data on response rates, but the evidence does not specify a precise timeline for harm. For patients who are refractory to avelumab, the risk of disease progression is significant, and alternative treatments such as combined ipilimumab and nivolumab may be considered (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). In summary, avelumab is an approved treatment for metastatic MCC with demonstrated efficacy in a subset of patients. The risk of non-response or progression is substantial, and patients who are refractory to avelumab have limited treatment options. The evidence does not support a causal link between avelumab and the development of MCC; rather, avelumab is used to treat the disease. Adequacy of warnings should include information on the potential for lack of response and immune-related adverse events, as well as the availability of alternative therapies for refractory cases.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, the evidence indicates that avelumab is not a cause of Merkel cell carcinoma. Avelumab is a therapeutic agent used to treat metastatic Merkel cell carcinoma. The primary risks associated with avelumab are lack of response or disease progression, not causation of the cancer itself.

What are the main risk factors for Merkel cell carcinoma?

Merkel cell carcinoma is primarily associated with chronic exposure to ultraviolet light and infection with the Merkel cell polyomavirus. Approximately 80% of cases are caused by the virus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/; https://pubmed.ncbi.nlm.nih.gov/35877101/).

What treatment options are available for patients who do not respond to avelumab?

For patients refractory to avelumab, combined immunotherapy with ipilimumab and nivolumab has shown promise. Studies have reported responses in a subset of patients (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). However, treatment options remain limited.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.